September 2014


**Highlights**

- Continue mandatory reporting of laboratory-confirmed influenza in fatal cases age 0-64 years by using CalREDIE or faxing the *Severe Influenza Case History Form* to 916-440-5984.
- Continue voluntary reporting of laboratory-confirmed influenza cases age 0-64 years requiring intensive care by using CalREDIE or faxing the *Severe Influenza Case History Form* to 916-440-5984.
- Report acute respiratory outbreaks as soon as possible using CalREDIE or faxing the *Preliminary Report of Communicable Disease Outbreak Form* to 510-620-3425 in the following situations:
  - Outbreaks in institutions (e.g. long term care facilities, prisons, sleepover camps) with at least one case of laboratory confirmed influenza in the setting of a cluster (≥2 cases) of ILI within a 72-hour period.
  - Associated with hospitalizations or fatalities.
  - Assessed as having public health importance (e.g., case(s) have recent exposure to swine, recent travel to an area where novel influenza is circulating, or contact with a confirmed case of swine or novel influenza).
- Encourage influenza testing in the following situations listed below. Note that rapid flu tests may vary in terms of sensitivity and specificity when compared with viral culture or reverse-transcriptase polymerase chain reaction (RT-PCR), with sensitivities ranging from approximately 50-70%. Laboratory testing with RT-PCR is the preferred testing method when there is strong clinical suspicion, even if the rapid test is negative.
  - Hospitalized, intensive care unit (ICU) and/or fatal cases with ILI
  - Acute respiratory outbreaks
    - ILI in any person where history of travel or recent close contacts or exposures within 10 days of symptom onset suggests concern for variant or novel influenza infection (e.g., swine (H3N2v of H1N2v) influenza,
influenza A/H7N9 or influenza A/H5) (see exact definitions at http://www.cdc.gov/flu/avianflu/h7n9/case-definitions.htm and http://www.cdc.gov/flu/avianflu/h5n1/testing.htm) * Influenza-like illness = fever (>100°F or 37.8°C) and cough and/or sore throat, in the absence of a known cause.

- Collect respiratory specimens for confirmation and further subtyping by RT-PCR at a Respiratory Laboratory Network (RLN) public health laboratory or the CDPH Viral and Rickettsial Disease Laboratory (CDPH-VRDL).
- Work with community partners, e.g., hospital clinicians and clinical laboratories, to remind them of the importance of saving specimens so that further subtyping and characterization can be performed at a public health laboratory.

**Diagnostic testing**

- Influenza RT-PCR testing is available at CDPH-VRDL and at 27 RLN laboratories.
- Upper respiratory samples suitable for RT-PCR include: nasopharyngeal (NP) swabs, nasal swabs, throat swabs, nasal aspirate, nasal washes, NP wash, and NP aspirate. For patients hospitalized with pneumonia, specimens from the lower respiratory tract should also be obtained. Lower respiratory tract samples suitable for RT-PCR include: bronchoalveolar lavage, bronchial wash, tracheal aspirate, and lung tissue.
- Place Dacron-tipped swabs in a standard container with 2-3 ml of viral transport media (VTM). Cotton or calcium alginate swabs are not acceptable for PCR testing.
- Specimens should be collected within the first 24-72 hours of onset of symptoms and no later than 5 days after onset of symptoms. The specimens should be kept refrigerated at 4°C and sent on cold packs if they can be received by the laboratory within 3 days of the date collected. If samples cannot be received by the laboratory within 3 days, they should be frozen at -70°C or below and shipped on dry ice. The CDPH-VRDL is able to receive specimens Monday through Friday.

**Recommendations for RLN laboratories**

- During the 2014-2015 influenza season, RLN laboratories are advised to continue broadened surveillance testing for all influenza viruses in persons with ILI, especially in ICU and fatal cases, as well as cases where history of travel or recent close contacts or exposures within 10 days of symptom onset suggests concern for variant or novel influenza infection (e.g., swine (H3N2v of H1N2v) influenza, influenza A/H7N9 or influenza A/H5) (see exact definitions at http://www.cdc.gov/flu/avianflu/h7n9/case-definitions.htm and http://www.cdc.gov/flu/avianflu/h5n1/testing.htm). RLN laboratories should also test specimens collected in the setting of acute respiratory outbreaks. In addition, the CDPH and CDC recommend testing of all hospitalized cases with ILI, as resources permit and at the discretion of the LHJ.
- To detect novel and possible reassorted viruses, it is important that laboratories use a full subtyping panel (inf A, H1, H3, pdm Inf A and pdm H1) when subtyping.
- Specimens with test results that are inconclusive or meet any of the following criteria should be submitted to CDPH-VRDL for further characterization:
  - Unsubtypeable results with cycle threshold (Ct) value for Flu A ≤ 35
Inconclusive results for influenza 2009 AH1N1 with Flu A Ct ≤ 35
Specimens with results suggesting presence of more than one influenza virus (co-infections)
Specimens with results suggesting presence of swine origin either
  - A/H3 virus: Inf A (+), H3 (+); pdm A (+); H1(neg) and pdm H1 (neg)
  - A/H1 virus: Inf A (+), H1 (+), pdm A (+); H3 (neg) and pdm H1 (neg)

• For ILI cases that test as Influenza NEGATIVE, VRDL will accept for further non-influenza respiratory virus testing specimens from cases that are have severe or fatal respiratory illness or are part of an outbreak. Please use this form: Non-Influenza testing form.
• RLN laboratories should refer to the Influenza Reference Examination Form for instructions on submission of specimens for further characterization at CDPH-VRDL.
• On a weekly basis, report test results to CDPH by emailing InfluenzaSurveillance@cdph.ca.gov. The worksheet will be distributed to all RLN labs in a separate email. If possible, please note whether test results have originated from outpatient, hospitalized, ICU or fatal patients.
• For fatal cases, refer available autopsy tissues to CDPH-VRDL for further testing and histopathologic analysis at CDC.
• On a case-by-case basis, refer to CDPH-VRDL specimens for antiviral resistance testing (e.g. a patient on treatment with persistently positive influenza PCR results).
• Submit samples to CDPH-VRDL for strain-typing and antiviral viral resistance (AVR) surveillance based on the Influenza RightSize Roadmap sample sizes for your laboratory for AVR testing. The sample sizes will be distributed to all RLN labs in a separate email.
• Generally, the CDPH requests the submission of influenza specimens as follows:
  - Submit at least one of each circulating influenza virus three times during the season
    • At the beginning of the influenza season
    • During the peak of the influenza season
    • At the end of the influenza season
  - Submit specimens as they are identified, rather than batching specimens
  - Submit original specimens; if virus has been cultured, also submit the cultured virus

Testing performed at CDPH-VRDL
Testing at CDPH-VRDL for the 2014-2015 influenza season will include outpatient ILI specimens submitted by sentinel providers and reference testing as requested by local public health laboratories.

For a subset of specimens, CDPH-VRDL and CDC will perform surveillance testing for antiviral resistance and strain-typing.

Questions regarding respiratory virus testing at CDPH-VRDL can be directed to Hugo Guevara [Hugo.Guevara@cdph.ca.gov or call 510-307-8565 or 510-248-9855 (cell)].
**Reporting of severe influenza cases**

- During the 2014-2015 influenza season, LHJs should continue mandatory reporting of laboratory-confirmed influenza in fatal cases age 0-64 years.
  - Once the resolution status of an influenza death is set as “confirmed” in CalREDIE, it will be included in the state weekly report and pediatric deaths will be reported to CDC.
  - If you plan on issuing a press release regarding your jurisdiction’s influenza death(s), please ensure the case(s) has been reported to the CDPH influenza staff (i.e., “confirmed” in CalREDIE or paper case report form has been faxed) and also notify the State Press Office (Office of Public Affairs, 916-440-7259) prior to the press release.
  - The resolution status should be set to “confirmed” in CalREDIE once the death meets the case definition. If any fatal cases reported by your county which meet the case definition are remaining in “suspect” status, please confirm them as soon as your investigation permits. This will help us minimize the lag in reporting of fatal cases as much as possible and allow our official counts in the state weekly report to be consistent with what is also being reported from LHJs.

- LHJs are strongly encouraged to continue voluntary reporting of laboratory-confirmed influenza cases age 0-64 years requiring intensive care.
  - Once the resolution status of an influenza intensive care admission is set as “confirmed” in CalREDIE, it may be included in the state weekly report.

**Reporting of non-TB respiratory outbreaks**

- CDPH also requests preliminary reporting of any acute respiratory outbreaks using CalREDIE or faxing the Preliminary Report of Communicable Disease Outbreak Form to 510-620-3425 in the following situations:
  - Outbreaks in institutions (e.g. long term care facilities, prisons, sleepover camps) with at least one case of laboratory confirmed influenza in the setting of a cluster (>2 cases) of ILI within a 72-hour period.
    - Even if it is not influenza season, influenza testing should occur when any resident has signs and symptoms that could be due to influenza, and especially when two residents or more develop respiratory illness within 72 hours of each other.
  - Outbreaks in institutions or congregate settings (e.g., schools, day camps) associated with hospitalizations or fatalities. If the setting is a hospice or long-term care facility, the LHJ should use its judgment as to whether the number of hospitalizations and/or fatalities is above baseline for that institution or setting.
  - Outbreaks in an institution, congregate setting or community where there has been recent exposure to swine of at least one case, or contact with a confirmed case of swine influenza (e.g. H3N2v or H1N2v).
  - Outbreaks in a community assessed by the LHJ as having public health importance.
- Laboratory confirmation can include any positive test performed by any clinical, commercial or local public health laboratory, including by positive rapid antigen test, direct fluorescence assay, culture or PCR. As rapid antigen tests may yield a relatively high proportion of false positive results when influenza prevalence is low, it is recommended that a positive rapid antigen test result be followed up with confirmatory testing using one of the other indicated methods. For cases of severe influenza, specimens should be sent for further sub-typing/characterization to the local public health laboratory or CDPH-VRDL, which will enable CDPH to closely monitor the strains of influenza viruses that may be causing severe disease or novel pandemic viruses and the emergence of antiviral resistance.

- LHJs should report fatal and ICU cases of laboratory-confirmed influenza to CDPH using CalREDIE or faxing the [Severe Influenza Case History Form](mailto:916-440-5984).

- Preliminary outbreak reports may be completed by LHJs in CalREDIE or by submitting the hardcopy [Preliminary Report of Communicable Disease Outbreak Form](mailto:CDOUTBREAK@cdph.ca.gov) by email to [CDOUTBREAK@cdph.ca.gov](mailto:CDOUTBREAK@cdph.ca.gov) or fax to 510-620-3425.